Marilyn J Hockenberry1, Mary C Hooke2, Cheryl Rodgers3, Olga Taylor4, Kari M Koerner5, Pauline Mitby6, Ida Moore5, Michael E Scheurer4, Wei Pan3. 1. Duke University School of Nursing, Durham, North Carolina, USA. Electronic address: marilyn.hockenberry@duke.edu. 2. University of Minnesota School of Nursing, Minneapolis, Minnesota, USA. 3. Duke University School of Nursing, Durham, North Carolina, USA. 4. Texas Children's Cancer and Hematology Centers/Baylor College of Medicine, Houston, Texas, USA. 5. University of Arizona College of Nursing, Tucson, Arizona, USA. 6. Children's Minnesota, Minneapolis, Minnesota, USA.
Abstract
CONTEXT: Cancer treatment symptoms play a major role in determining the health of children with cancer. Symptom toxicity often results in complications, treatment delays, and therapy dose reductions that can compromise leukemia therapy and jeopardize chances for long-term survival. Critical to understanding symptom experiences during treatment is the need for exploration of "why" inter-individual symptom differences occur; this will determine who may be most susceptible to treatment toxicities. OBJECTIVES: This study examined specific symptom trajectories during the first 18 months of childhood leukemia treatment. Symptom measures included fatigue, sleep disturbances, pain, nausea, and depression. METHODS: Symptom trajectories of 236 children with leukemia three to 18 years old were explored prospectively over four periods: initiation of post-induction therapy, four and eight post-induction therapy, and the last time point was at the beginning of maintenance/continuation therapy. Latent class growth analysis was used to classify patients into distinctive groups with similar symptom trajectories based on patients' response patterns on the symptom measures over time. RESULTS: Three latent classes of symptom trajectories were identified and classified into mild, moderate, and severe symptom trajectories. The only demographic characteristic with a significant relationship to membership in the latent class symptom trajectories was race/ethnicity. All other demographic characteristics including leukemia risk levels showed no significant relationships. CONCLUSION: This study is unique in that groups of patients with similar symptoms were identified rather than groups of symptoms. Further research using latent class growth analysis is needed.
CONTEXT: Cancer treatment symptoms play a major role in determining the health of children with cancer. Symptom toxicity often results in complications, treatment delays, and therapy dose reductions that can compromise leukemia therapy and jeopardize chances for long-term survival. Critical to understanding symptom experiences during treatment is the need for exploration of "why" inter-individual symptom differences occur; this will determine who may be most susceptible to treatment toxicities. OBJECTIVES: This study examined specific symptom trajectories during the first 18 months of childhood leukemia treatment. Symptom measures included fatigue, sleep disturbances, pain, nausea, and depression. METHODS: Symptom trajectories of 236 children with leukemia three to 18 years old were explored prospectively over four periods: initiation of post-induction therapy, four and eight post-induction therapy, and the last time point was at the beginning of maintenance/continuation therapy. Latent class growth analysis was used to classify patients into distinctive groups with similar symptom trajectories based on patients' response patterns on the symptom measures over time. RESULTS: Three latent classes of symptom trajectories were identified and classified into mild, moderate, and severe symptom trajectories. The only demographic characteristic with a significant relationship to membership in the latent class symptom trajectories was race/ethnicity. All other demographic characteristics including leukemia risk levels showed no significant relationships. CONCLUSION: This study is unique in that groups of patients with similar symptoms were identified rather than groups of symptoms. Further research using latent class growth analysis is needed.
Authors: Mary C Hooke; Cheryl Rodgers; Olga Taylor; Kari M Koerner; Pauline Mitby; Ida Moore; Michael E Scheurer; Marilyn J Hockenberry; Wei Pan Journal: Cancer Nurs Date: 2018 Nov/Dec Impact factor: 2.592
Authors: Marilyn J Hockenberry; Wei Pan; Michael E Scheurer; Mary C Hooke; Olga Taylor; Kari Koerner; David Montgomery; Susan Whitman; Pauline Mitby; Ida Moore Journal: Biol Res Nurs Date: 2019-07-17 Impact factor: 2.522
Authors: Mary C Hooke; Daniel Hatch; Marilyn J Hockenberry; Susan Whitman; Ida Moore; David Montgomery; Kari Marano; Pauline Mitby; Michael E Scheurer; Olga Taylor; Wei Pan Journal: J Pediatr Oncol Nurs Date: 2020-03-06 Impact factor: 1.636
Authors: Mary C Hooke; Michelle A Mathiason; Audrey Blommer; Jessica Hutter; Pauline Mitby; Olga Taylor; Michael E Scheurer; Alicia S Kunin-Batson; Wei Pan; Marilyn J Hockenberry Journal: Cancer Nurs Date: 2022 Mar-Apr 01 Impact factor: 2.592
Authors: Austin L Brown; Kimberly P Raghubar; Olga A Taylor; Melanie Brooke Bernhardt; Lisa S Kahalley; Wei Pan; Philip J Lupo; Marilyn J Hockenberry; Michael E Scheurer Journal: Support Care Cancer Date: 2020-09-14 Impact factor: 3.603
Authors: Marita Partanen; Sean Phipps; Kathryn Russell; Doralina L Anghelescu; Joshua Wolf; Heather M Conklin; Kevin R Krull; Hiroto Inaba; Ching-Hon Pui; Lisa M Jacola Journal: J Pediatr Psychol Date: 2021-02-19
Authors: Austin L Brown; Pagna Sok; Olga Taylor; John P Woodhouse; M Brooke Bernhardt; Kimberly P Raghubar; Lisa S Kahalley; Philip J Lupo; Marilyn J Hockenberry; Michael E Scheurer Journal: J Pain Symptom Manage Date: 2020-09-01 Impact factor: 3.612